TY  - JOUR
TI  - Lipase inhibitor orlistat: An old but still effective weapon
AB  - Nowadays, the pharmacological treatment of obesity has increased its significance due to the failure of conventional obesity treatments. Thus, Orlistat which is a lipase inhibitor is being used as an anti-obesity medication in many countries. In this study, the effect of Orlistat on weight loss and metabolic parameters in Turkish female patients was evaluated. Female patients with diagnosis of obesity who were followed up in Kutahya Training and Research Hospital were evaluated via retrospective observation. A total of 100 patients with body mass index (BMI-kg/m2) of > 40, who were regularly followed up every month and compliant with their treatment (diet, exercise and orlistat) were included in the study. Monthly values of weight loss and BMI, along with baseline - 12th week values of fasting blood glucose, insulin, glycated hemoglobin (HBA1c), lipid profile, creatinine, aspartate aminotransferase, alanine aminotransferase and thyroid- stimulating hormone of patients who received orlistat 120 mg three times a day for 12 weeks in addition to diet and exercise,were evaluated. Mean weight loss values of the patients using orlistat in the 1st, 2nd and 3rd month were found as - 3.6 ± 0.5 kg, -2.2 ± 0.1 kg and -1.8 kg, respectively (p <0.0001). The median BMI values at baseline, in 1st, 2nd and 3rd months were 43.1 kg/m2 (40.0- 47.0), 41.7 kg/m2 (39.0-45.4), 40.5 kg/m2 (38.2-44.9), and 39.8 kg/m2 (37.2-44.2), respectively (p <0.0001). Significant decreases in glycemic parameters including fasting blood glucose, HBa1c, and fasting insulin levels were provided (all, p <0.0001). Furthermore, positive effects were found on all lipid profiles except HDL cholesterol (p <0.05). Even in an early period of 12 weeks, Orlistat treatment was observed to significantly reduce BMI, insulin, HBA1c, total cholesterol, high-density lipoprotein and triglyceride values of Turkish female patients. Orlistat usage with diet and exercise can be beneficial for reducing the risk of glucose intolerance and cardiovascular disease.
AU  - Onbasi, Kevser
AU  - Aydın, Bünyamin
DO  - 10.5455/medscience.2021.05.191
PY  - 2021
JO  - Medicine Science
VL  - 10
IS  - 4
SN  - 2147-0634
SP  - 1406
EP  - 1411
DB  - TRDizin
UR  - http://search/yayin/detay/504678
ER  -